Please check your internet connection and try again.
## Clobazam (Oral)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is a Schedule IV controlled substance.
### Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label: Other seizure types and anxiety disorders.
### Adult Dosing
* **LGS:**
* Initiate at 5 mg twice daily.
* Increase dose by 5-10 mg every week.
* Usual maintenance dose: 10-20 mg twice daily.
* Maximum dose: 20 mg twice daily (40 mg/day).
* **Titration:** Doses should be increased gradually to minimize potential adverse effects.
### Pediatric Dosing
* **LGS (2 to <10 years or <30 kg):**
* Initiate at 5 mg once daily.
* Increase dose by 2.5-5 mg every week.
* Usual maintenance dose: 5-10 mg twice daily.
* Maximum dose: 10 mg twice daily (20 mg/day).
* **LGS (≥10 years or ≥30 kg):**
* Same as adult dosing: Initiate at 5 mg twice daily, titrate up to 20 mg twice daily.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are established, but consider lower starting doses and slower titration.
* **Renal Impairment:** No specific dosage adjustments are established. Use with caution.
* **Concomitant Medications:**
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam levels. Consider reducing clobazam dose.
* **Strong CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam levels. Consider reducing clobazam dose.
* **Strong CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam levels. Consider increasing clobazam dose.
* **CNS Depressants (e.g., opioids, alcohol):** Additive CNS depression may occur.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Sleep apnea.
### Adverse Effects
* **Common:** Somnolence, drooling, constipation, decreased appetite, aggression, irritability, difficulty with coordination, respiratory tract infections.
* **Serious:** Suicidal behavior and ideation, severe dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms, dependence, behavioral changes, respiratory depression, paradoxical reactions.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and potentially fatal outcomes.
* **CYP Enzyme Inhibitors/Inducers:** Potential for significant changes in clobazam concentrations (see Dose Adjustments).
* **Antiepileptic Drugs (AEDs):** May alter the pharmacokinetics of other AEDs.
### Monitoring
* **Efficacy:** Monitor for seizure frequency and severity.
* **Safety:** Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of withdrawal.
* **Suicidality:** Monitor for suicidal thoughts and behaviors.
* **Drug Interactions:** Monitor for potential interactions, especially with CYP enzyme modulators and other CNS depressants.
### Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing.
* Tapering is necessary upon discontinuation to avoid withdrawal symptoms.
* Clobazam can be associated with development of tolerance and dependence.
* Be aware of the increased risk of serious dermatologic reactions, especially in patients with a history of sulfonamide allergies.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical judgment. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
